Via Christi first to perform new heart procedure
The most common cause of heart attacks and strokes is Coronary Artery Disease. It is caused by plaque buildup along the walls of the arteries in the heart.
Over time, this causes the arteries to narrow, blocking blood circulation to the heart. Once the disease has progressed far enough, it often requires surgical intervention.
One of the treatments for the disease in its advanced stage is angioplasty, which involves the insertion of stents in the artery to restore blood flow. A wire is threaded through the circulatory system, up to the artery, and a small balloon is inflated, which expands a small wire mesh called a stent, that helps hold the artery open and restore blood flow.
Surgeons often use techniques that involve scoring or cutting the artery wall to break up calcified deposits, or they use catheters with rotating blades or lasers. Via Christi is participating in the testing of a new device that uses sound waves to break up the deposits.
It's called TECTONIC Coronary Artery Disease Intravascular Lithotripsy. The device is produced by Abbott Laboratories, a company that manufactures diagnostic and medical devices, as well as generic pharmaceuticals and other products.
Via Christi St. Francis was the first hospital in the nationwide investigational study of Abbott's IVL to successfully treat a patient. Interventional Cardiologist Bassem Chehab, MD, performed the procedure.
Ava Jones announces cancer is 99% clear
'Participating in the TECTONIC CAD IVL trial explores a promising new technology that could significantly improve outcomes for patients with severe coronary artery calcification,' says Dr. Chehab, in a news release from Via Christi. 'By participating in the potential of intravascular lithotripsy, we're helping take a vital step towards enhancing patient care and offering more effective treatment options for this challenging condition.'
Chehab adds, 'Being able to treat the first patient ever in a novel and groundbreaking technology solidifies the global and national trust in the expertise of Via Christi as a leader in advanced cardiac care regionally and nationally.'
The TECTONIC CAD IVL is undergoing clinical trials and is not currently commercially available. It can take 3 to 7 years for a new medical device to successfully complete a clinical trial and receive FDA approval for widespread use.
For more information about Ascension Via Christi Cardiology, click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Rapid Expansion and Innovation Drive $36 Billion Global Point-of-Care Diagnostics Market, Says New Kalorama Report
ARLINGTON, Va., July 29, 2025 /PRNewswire/ -- A new report from Kalorama Information reveals that the global point-of-care (POC) diagnostics market surged past $36 billion in 2024, with projections pointing to continued growth through 2029. The twelfth edition of Worldwide Market for Point-of-Care Diagnostic Tests, 12th Edition highlights how decentralization of healthcare, rapid innovation, and consumer-driven demand are reshaping how and where diagnostic tests are performed—from traditional clinical settings to homes, workplaces, and remote environments. "POC testing is no longer a fringe segment—it is a central pillar of modern diagnostics," said Melissa Elder, Senior Analyst at Kalorama Information. "We see industry leaders like Abbott, Dexcom, Roche, Danaher, and Exact Sciences innovating aggressively, with POC solutions spanning blood gases, infectious disease, colon cancer, glucose monitoring, and more." The report identifies major growth opportunities in oncology, stroke, dementia, cardiac markers, and glucose management. With transportable and handheld devices becoming more widely available, the reach of point-of-care testing is extending to urgent care centers, disaster relief zones, and at-home monitoring. While the market is recovering from the COVID-19 testing surge of 2020–2022, momentum continues thanks to emerging technologies and the expanding need for fast, accurate, and accessible diagnostics. Trends Shaping the Future of POC Diagnostics: Wearables and mobile health tools Telehealth integration CRISPR and microfluidics innovation Multiplexed and AI-enabled testing Regulatory challenges and LDT policy changes The rise of non-invasive and consumer-friendly testing China's expanding role in the global POC landscape Key Takeaways from the Report: $36 Billion in Global Revenues (2024): Driven by demand in physician offices, clinics, and mobile care, with steady mid-single-digit CAGR expected through 2029. Top Growth Areas: Oncology, stroke, dementia, cardiac, and continuous glucose monitoring (CGM). Next-Gen Tech Impact: Innovations in CRISPR diagnostics, biosensors, and AI are transforming point-of-care capabilities. POC Molecular Diagnostics Rise: Originally accelerated by COVID-19, molecular POC testing is gaining relevance in emergency care and field screening worldwide. Consumer-Led Prevention: Wearables and Bluetooth-enabled tools support proactive health monitoring. Market Leaders and Competitive Landscape "Abbott leads the global market with over 25% share due to its expansive POC portfolio," said Elder. "Dexcom and Roche are advancing CGM and coagulation testing, while Exact Sciences is driving growth in colon cancer diagnostics. Danaher's Beckman Coulter continues to deliver in blood, cancer, and infectious disease testing." An Essential Industry Resource The report is a vital tool for product developers, investors, and healthcare strategists navigating market trends and emerging opportunities. It answers critical questions such as: Where is POC testing growing fastest? What technologies are reshaping diagnostic accessibility? How are regulations and reimbursement shaping adoption? What are the most promising new test types and applications? What's Inside: Global market forecasts through 2029 In-depth segmentation across 10+ test categories Venue analysis (hospital, clinic, retail, home) Competitive landscape profiles and regulatory updates Access the Report Worldwide Market for Point-of-Care Diagnostic Tests, 12th Edition is now available: To request the report or schedule a briefing:Sheri Davie – Kalorama Information Sales For media inquiries:Richa Singh – VP, Strategic & Insights About Kalorama InformationKalorama Information, part of Science and Medicine Group, is a leading publisher of independent market research in medical diagnostics, biotechnology, and life sciences. Our reports help global healthcare organizations, investors, and innovators make informed decisions with confidence. View original content to download multimedia: SOURCE Kalorama Information
Business Insider
a day ago
- Business Insider
FDA approves Apellis' Empaveli for treatment of C3 glomerulopathy
Apellis (APLS) Pharmaceuticals announced that the U.S. Food and Drug Administration has approved EMPAVELI as the first treatment for C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States. 'I'm excited to now have a highly effective therapy for a broad range of patients living with C3G and primary IC-MPGN,' said Carla Nester, M.D., MSA, FASN, lead principal investigator for the VALIANT study, professor of internal medicine and pediatrics and director of pediatric nephrology, University of Iowa Stead Family Children's Hospital. 'With standard of care, patients living with these rare and severe diseases frequently progress to kidney failure, necessitating lifelong dialysis and/or a kidney transplant. Given the urgent need, particularly in children, the approval of EMPAVELI marks a pivotal moment in the treatment of rare kidney diseases.' In the Phase 3 VALIANT study, EMPAVELI demonstrated an unprecedented 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits as measured by C3 staining, compared to placebo. The positive results were consistent across adolescent and adult patients with C3G and primary IC-MPGN, and in C3G patients with post-transplant disease recurrence.
Yahoo
2 days ago
- Yahoo
After delay, Kalvista wins FDA OK for drug to treat rare swelling disorder
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: After a delay due to 'resource constraints,' the Food and Drug Administration on Monday approved Kalvista Pharmaceuticals' pill Ekterly to treat swelling attacks in people with the rare disorder hereditary angioedema. Ekterly is the first oral drug to treat hereditary angioedema, or HAE, attacks, competing with shots like Firazyr from Takeda and Ruconest from Pharming. Analysts have estimated Ekterly, Kalvista's first marketed drug, could bring in $600 million a year in U.S. sales at its peak. The FDA delayed the decision beyond its June 17 deadline, Kalvista said, because of a 'heavy workload and limited resources.' While Kalvista awaited its decision, the FDA granted approval to another HAE drug, CSL's Andembry, a preventive shot that won't compete directly with Ekterly. Dive Insight: Kalvista set a price of $16,720 per dose, which consists of two 600 milligram tablets of Ekterly, known scientifically as sebetralstat. A company spokesperson stated Kalvista 'priced Ekterly competitively with existing therapies, reflecting the innovation it brings to the HAE community,' noting that it's the first new drug in more than a decade. Under the FDA's approval, people experiencing a HAE attack can take a second dose within three hours if they don't get symptom relief, while people taking Firazyr must wait six, a protocol that could give Ekterly a competitive advantage, Stifel analyst Paul Matteis wrote in a note to clients. Moreover, people using Firazyr and Ruconest must receive training before they can self-inject. The drug won approval based on a trial of 110 people, which found that people who took Ekterly after an attack achieved symptom relief in a median of two hours following a dose within a 12-hour window in which the drug's effectiveness was measured. Fewer than 50% of people who took a placebo in the trial experienced symptom relief within 12 hours. More HAE attacks were resolved in people who took Ekterly within 24 hours, at about 50% compared to 27% in those who took placebo. Kalvista shares rose 24% in early trading, recovering all of the losses following the FDA's delay. Matteis took an optimistic view of the drug, writing that Ekterly's 'injectable-like efficacy has the potential to take a meaningful share, and potentially grow, the on-demand HAE market, which has remained relatively stable.' Recommended Reading Ionis, Astrazeneca win FDA approval of competitor to Alnylam drug Solve the daily Crossword
